Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
European Journal of Haematology|April 2, 2015
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessmentMoshe E Gatt, Izhar Hardan, Evgeni Chubar, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
EMBO Reports|January 21, 2025
High CDC20 levels increase sensitivity of cancer cells to MPS1 inhibitorsSiqi Zheng, Linoy Raz, Lin Zhou, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.
Nature Medicine|September 5, 2025
Pridopidine in early-stage manifest Huntington's disease: a phase 3 trialRalf Reilmann, Andrew Feigin, Anne E Rosser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.
Vaccines|May 5, 2021
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 VaccinationAbdulla Watad, Gabriele De Marco, Hussein Mahajna, et al.
Nature Communications|September 9, 2024
Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damageJohanna Zerbib, Marica Rosaria Ippolito, Yonatan Eliezer, et al.
Pageof 8